Trending

24/7MN (NASDAQ: EVFM) EvoFem shares are moving up in pre-market as news of the last subject last visit in PHASE 3 “EvoGuard” trial evaluating Phexxi for the prevention of chlamydia and Gonorrhea in woman.

Shares are .75 and up modestly at 4.8% on more than 772k in volume and 1474 trades as of this post.

https://www.prnewswire.com/news-releases/evofem-announces-completion-of-last-subject-last-visit-lslv-in-registrational-phase-3-evoguard-trial-evaluating-phexxi-for-the-prevention-of-chlamydia-and-gonorrhea-in-women-301596733.html

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist